US EditionLEQEMBI® IQLIK™(lecanemab-Irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - Biogen (NASDAQ:BIIB)
LEQEMBI IQLIK offers a 15-second at-home injection to continue Alzheimer's treatment after 18 months, maintaining clinical benefits with fewer systemic reactions, Biogen said.
- TIME named Biogen in Cambridge, Massachusetts' LEQEMBI IQLIK, a subcutaneous autoinjector, as one of the `Best Inventions of 2025` in Medical and Healthcare.
- Offering an at-home option, LEQEMBI IQLIK shortens administration to about 15 seconds and lets patients and care partners avoid infusion-center visits after the 18-month initiation dose.
- Phase 3 data show the Clarity AD clinical trial reduced clinical decline on CDR-SB by 27% and improved caregiver-reported ADCS-MCI-ADL by 37%, with safety studied in over 600 patients.
- Clinicians should consider that ARIA occurred in 21% with LEQEMBI versus 9%, with symptomatic ARIA in 3% and serious ARIA in 0.7%.
- With regulatory momentum, the treatment received U.S. approval in August 2025 and launched on October 6, 2025, while Eisai leads global submissions and LEQEMBI is approved in 50 countries with review in 10.
54 Articles
54 Articles
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s 'Best Inventions of 2025”
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, 'Biogen”) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by TIME as one of the 'Best Inventions…
keenesentinel.com
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation…
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - Biogen (NASDAQ:BIIB)
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions…
Alzheimer?s Revolution Biogen and Eisais Trailblazing Innovations Forge New Paths in Treatment,
'A Leap Forward in Alzheimer's Treatment: Biogen and Eisai's Innovations Garner Global Recognition' Biogen Inc. and Eisai Co., Ltd., two of the most pioneering companies in the pharmaceutical landscape, have achieved remarkable milestones in the quest to tackle Alzheimer's disease (AD). The spotlight shines brightly on their innovative developments: LEQEMBI IQLIK, a convenient subcutaneous autoinjector, and BIIB080, an investigational tau-target…
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025” – DIR HONGKONG
TOKYO and CAMBRIDGE, Mass., Oct. 14, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD)has been selected by TIME as one of the …
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
